Stockwatch

Date	Sym	Type	Headline
2024-04-25 10:00	UU:TLSA	News Release200	Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
2024-04-23 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
2024-04-22 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
2024-04-19 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today(TM)
2024-04-18 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
2024-04-11 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
2024-03-05 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease
2024-01-08 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
2024-01-05 09:30	UU:TLSA	News Release200	Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
2024-01-05 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
2023-12-19 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
2023-12-04 07:10	UU:TLSA	News Release200	Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
2023-11-30 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
2023-11-01 07:00	UU:TLSA	News Release200	Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
2023-10-18 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
2023-10-17 03:29	UU:TLSA	News Release200	Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
2023-10-16 08:01	UU:TLSA	News Release200	Tiziana Life Sciences reports six-month PET scan results for MS patients
2023-10-16 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
2023-10-13 07:00	UU:TLSA	News Release200	Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
2023-10-11 07:00	UU:TLSA	News Release200	Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
2023-09-26 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
2023-09-12 08:21	UU:TLSA	News Release200	Tiziana Life Sciences' Alzheimer's treatment validated in new study
2023-09-08 07:00	UU:TLSA	News Release200	Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-06 07:00	UU:TLSA	News Release200	Study Validating MoA of Intranasal Foralumab in Alzheimer ¢ € ™s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
2023-08-23 10:30	UU:TLSA	News Release200	Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
2023-08-23 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
2023-08-17 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
2023-08-15 09:29	UU:TLSA	News Release200	Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
2023-08-15 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer ¢ € ™s Disease
2023-08-01 08:01	UU:TLSA	News Release200	Proactive Analyst expects "some good news over the next 1-2 months" from Tiziana Life Sciences
2023-07-21 16:15	UU:TLSA	News Release200	Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
2023-06-13 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
2023-06-05 10:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
2023-05-25 07:00	UU:TLSA	News Release200	Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
2023-05-23 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
2023-05-17 07:00	UU:TLSA	News Release200	Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
2023-05-05 10:51	UU:TLSA	News Release200	Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst